Valuation dashboard for BioRestorative Therapies, Inc. (BRTX) with P/E N/A, P/B 0.76, EV/EBITDA -0.07 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100.
Analysis Summary
BioRestorative Therapies, Inc. reported revenue of $359700 in the most recent fiscal year, growing at a 5-year CAGR of 36.1%.
Trailing-twelve-month margins: gross margin 92.1%, operating margin -39.7%, net margin -30.9%.
At the current price of $2.55, BRTX has negative trailing earnings (P/E not meaningful) and an ROE of -423.84%. Market capitalisation stands at $4M.
Balance sheet quality for BRTX: current ratio of 0.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.76 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-46.23 |
| vs Current Price | -1912.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BRTX | BioRestorative Therapies, Inc. | $4M | 0.76 | -423.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.55 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -423.84% |
| Return on Invested Capital | -464.86% |
| Return on Assets | -238.27% |
| Gross Margin | 92.09% |
| Operating Margin | -3975.00% |
| Net Margin | -3089.55% |
Related companies: BOLT · COCP · DWTX · EDSA · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of BRTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks